Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Cost of Revenue (2016 - 2025)

OptimizeRx's Cost of Revenue history spans 13 years, with the latest figure at $8.6 million for Q3 2025.

  • For Q3 2025, Cost of Revenue rose 8.76% year-over-year to $8.6 million; the TTM value through Sep 2025 reached $38.0 million, up 15.17%, while the annual FY2024 figure was $32.7 million, 14.42% up from the prior year.
  • Cost of Revenue for Q3 2025 was $8.6 million at OptimizeRx, down from $10.6 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $10.6 million in Q2 2025 and bottomed at $5.0 million in Q2 2022.
  • The 5-year median for Cost of Revenue is $7.1 million (2024), against an average of $7.3 million.
  • The largest annual shift saw Cost of Revenue soared 57.46% in 2021 before it dropped 19.62% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $7.9 million in 2021, then dropped by 9.1% to $7.2 million in 2022, then surged by 46.22% to $10.5 million in 2023, then decreased by 2.23% to $10.3 million in 2024, then decreased by 16.92% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Cost of Revenue are $8.6 million (Q3 2025), $10.6 million (Q2 2025), and $8.6 million (Q1 2025).